PT - JOURNAL ARTICLE AU - Jagadeesan, M AU - Ganeshkumar, Parasuraman AU - Kaur, Prabhdeep AU - Sriramulu, Hemalatha Masanam AU - Sakthivel, Manikandanesan AU - Rubeshkumar, Polani AU - Raju, Mohankumar AU - Murugesan, Lakshmidevi AU - Ganapathi, Raajkumar AU - Srinivasan, Mahalakshmi AU - Sukumar, Aswini AU - Ilangovan, Kumaravel AU - Reddy, Madhusudhan AU - Shanmugam, Divyadarshini AU - Govindasamy, Prakash AU - Murhekhar, Manoj TI - Epidemiology of COVID-19 and effect of public health interventions, Chennai, India, March - October 2020 AID - 10.1101/2021.04.21.21255852 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.21.21255852 4099 - http://medrxiv.org/content/early/2021/04/25/2021.04.21.21255852.short 4100 - http://medrxiv.org/content/early/2021/04/25/2021.04.21.21255852.full AB - Objectives To describe the public health strategies and their effect in controlling the COVID-19 pandemic from March to October 2020 in Chennai, India.Setting Chennai, a densely populated metropolitan city in Southern India, was one of the five cities which contributed to more than half of the COVID-19 cases in India.Participants We collected the de-identified line list of all the 192,450 COVID-19 case-patients reported from 17 March to 31 October 2020 in Chennai and their contacts for the analysis. We defined a COVID-19 case-patient based on the RT-PCR positive test in one of the Government approved labs.Outcome measures The primary outcomes of interest were incidence of COVID-19 per million population, case fatality ratio, deaths per million and the effective reproduction number (Rt). We also analysed the indicators for surveillance, testing, contact tracing and isolation.Results Of the 192,450 RT-PCR confirmed COVID-19 case-patients reported in Chennai from 17 March-31 October 2020, 114,889 (60%) were males. The highest incidence was 41,064 per million population among the 61-80 years. The incidence peaked during June 2020 at 5239 per million and declined to 3,627 per million in October 2020. The city reported 3,543 deaths, with a case fatality ratio (CFR) of 1.8% and the crude death rate was 431 per million. When lockdown began, Rt was high (4.2) in March and fluctuated from April to June 2020. The Rt dropped below one by the first week of July and remained so until October 2020, even with the relaxation of restrictionsConclusion The combination of public health strategies controlled the COVID-19 epidemic in a large, densely populated city in India. We recommend continuing the interventions to prevent resurgence, even as vaccination is being rolled out.StrengthsWe did a comprehensive analysis of COVID-19 strategies and outcome in a large, densely populated metropolitan city in India.We documented that the community-centric public health strategies were feasible and effective in controlling the COVID-19 outbreak even in a large, thickly populated cityThe lessons learnt are relevant to similar settings in low-and middle-income countries. Given the ongoing multiple waves of COVID-19 and the difficulty in controlling the transmission, our experience and lessons learnt will be valuable for policymakers and scientific advisors globallyLimitationsWe analysed the data available from the GCC database and not from the hospitals where patients with moderate to severe illness were admitted. Hence, we could not report the severity of illness among admitted patients.Second, the COVID-19 incidence might have been underestimated while testing was low during the early phase of the epidemicCompeting Interest StatementAll authors have completed the ICMJE uniform disclosure form and declare: support from the Health and Family Welfare Department, Government of Tamil Nadu, India; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The de-identified data were extracted from the GCC surveillance database after strict data protection protocols agreed between GCC and ICMR-NIE. We obtained approval from the Institutional Ethics Committee of ICMR-NIE for the study, with the project ID NIE/IHEC/202004-07. Since we did not interview the patients and used only the de-identified data from the database for the study, informed consent was not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request.